TITLE

Can-Fite's CF101 delivers can-do performance in RA

AUTHOR(S)
Powers, Marie
PUB. DATE
December 2013
SOURCE
BioWorld Today;12/24/2013, Vol. 24 Issue 246, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that Can-Fite Biopharma Ltd. impressed investors with results from its Phase IIb trial results of CF101 drug product as a monotherapy for rheumatoid arthritis (RA). It says that the study demonstrated statistically significant quality compared to placebo in reducing RA signs and symptoms. It mentions that the company will not wait for a partnership to move ahead with Phase III plans for the drug.
ACCESSION #
93336605

 

Related Articles

  • Dry-Eye Phase III Trial Enrolled, OphthaliX 'Wets' Oral Appetite. Osborne, Randy // BioWorld Today;3/19/2013, Vol. 24 Issue 52, p1 

    The article reports that OphthaliX has tackled its first-in-class A3 adenosine receptor agonist CF101 in a 24-week, 236-patient placebo-controlled Phase III trial. It states that serendipity data provided by patients in a rheumatoid arthritis (RA) trial with CF101 led to dry-eye syndrome (DES)...

  • CLINIC ROUNDUP.  // BioWorld Today;7/15/2009, Vol. 20 Issue 134, p6 

    This section offers news briefs related to several clinical trials. A Phase I/II trial with CF102 for the treatment of hepatitis C virus by Can-Fite BioPharma of Petach Tikva, Israel will begin to enroll patients. Enrollment for the first of two ongoing blinded, placebo-controlled, multicenter,...

  • Minocycline is effective treatment for early-onset rheumatoid arthritis. Haire, C.E.; O'Dell, J.R. // Geriatrics;Sep97, Vol. 52 Issue 9, p107 

    Studies the treatment of early rheumatoid arthritis with minocycline or placebo. How antibiotic minocycline improves symptoms of rheumatoid arthritis; Subjects of the study; Evaluation of the patients' symptoms severity and erythrocyte sedimentation rates (SDR) at the baseline during the treatment.

  • The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3-and 6-month response rates in trials of biological agents.  // International Journal of Advances in Rheumatology;2010, Vol. 8 Issue 1, p28 

    The article reports on the findings of the registration trials which examined the sufficiency of three months of placebo in determining the efficacy of six different biological disease-modifying antirheumatic drugs (DMARDs) for the treatment of patients with rheumatoid arthritis.

  • CAN-FITE BIOPHARMA INITIATES CF102 TRIAL FOR LIVER CANCER.  // Worldwide Biotech;May2009, Vol. 21 Issue 5, p8 

    This article reports on the plan of Can-Fite BioPharma of Israel to conduct a I/II clinical trial with CF102 for the treatment of liver cancer in 2009. Can-Fite announced that it will start enrolling patients for the clinical trial. The company will investigate the safety and efficacy of CF102...

  • CLINIC ROUNDUP.  // BioWorld Today;5/6/2008, Vol. 19 Issue 88, p4 

    This section offers news briefs on the pharmaceutical industry. Anesiva Inc. has announced the publication of data from a Phase III trial of Zingo powder intradermal injection in "Journal Pediatrics." Can-Fite BioPharma has successfully completed a Phase I trial with its second pipeline drug,...

  • Clinic Roundup.  // BioWorld Today;8/2/2011, Vol. 22 Issue 148, p7 

    The article reports on the enrollment in a Phase II/III trial of CF101, a drug for psoriasis, developed by Can-Fite BioPharma Ltd.

  • OTHER NEWS TO NOTE.  // BioWorld Today;1/2/2008, Vol. 19 Issue 1, p2 

    This section offers news briefs in the world of biotechnology. According to Acambis plc, it completed delivery of the entire 2.7 million doses of its ACAM2000 smallpox vaccine to the U.S. Centers for Disease Control and Prevention ahead of schedule. Two worldwide research laboratories have been...

  • CLINIC ROUNDUP.  // BioWorld Today;1/9/2008, Vol. 19 Issue 6, p2 

    This section offers news briefs related to clinical trials of drugs. Arena Pharmaceuticals Inc. said that initial results of trials for APD668 suggest that glucose-dependent insulinotropic receptors might improve glucose control in patients with Type II diabetes. Can-Fite BioPharma Ltd. was...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics